Zobrazeno 1 - 10
of 510
pro vyhledávání: '"small dense low-density lipoprotein"'
Publikováno v:
Lipids in Health and Disease, Vol 23, Iss 1, Pp 1-9 (2024)
Abstract Objective Small dense low-density lipoprotein cholesterol (sdLDL-C), as an emerging atherogenic factor of cardiovascular diseases, requires additional tests. We aimed to establish a sdLDL-C equation using standard lipid profile and evaluate
Externí odkaz:
https://doaj.org/article/c97d859038f7467c8952c66e5d1371a8
Autor:
Qing Yang, Yutong Zou, Yanlin Lang, Jia Yang, Yucheng Wu, Xiang Xiao, Chunmei Qin, Yuancheng Zhao, Fang Liu
Publikováno v:
Renal Failure, Vol 46, Iss 2 (2024)
Aims This study aimed to investigate the correlations between estimated small dense low-density lipoprotein-cholesterol (esd-LDL-c) and the development of end-stage kidney disease (ESKD), cardiovascular mortality, and all-cause mortality in individua
Externí odkaz:
https://doaj.org/article/3f1c9c3c953c4b1cbf7467b90b5fbd5b
Autor:
Shouxing Yang, Jing Xu
Publikováno v:
Journal of Diabetes Investigation, Vol 15, Iss 5, Pp 634-642 (2024)
ABSTRACT Introduction It is demonstrated that elevated small dense low‐density lipoprotein cholesterol (sdLDL‐C), and reduced high‐density lipoprotein cholesterol (HDL‐C) is associated with Metabolic dysfunction‐associated fatty liver disea
Externí odkaz:
https://doaj.org/article/b6a6ebe4463548a1bf17b3aae6e692aa
Publikováno v:
Journal of Diabetes Investigation, Vol 15, Iss 4, Pp 491-499 (2024)
Abstract Aims/Introduction To explore the association between estimated small dense low‐density lipoprotein cholesterol (sdLDL‐C) and the risk of incident nonalcoholic fatty liver disease (NAFLD) in nonobese populations. Materials and Methods Thi
Externí odkaz:
https://doaj.org/article/9597baac9a804b66bf2187a36d820332
Publikováno v:
Diabetes, Metabolic Syndrome and Obesity, Vol Volume 17, Pp 1523-1532 (2024)
Xiaoli Zhu,1 Yijun Chen,1 Mingan Zhu,2 Jinxi Hu3 1Department of Laboratory Medicine, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Taizhou, Zhejiang, People’s Republic of China; 2Department of Medical Laboratory, R
Externí odkaz:
https://doaj.org/article/b18b344ef0454fa99692426d32adf680
Autor:
Lin, Chien-Yu a, b, c, Huey-Jen Hsu, Sandy d, Lee, Hui-Ling e, Wang, Chikang c, Sung, Fung-Chang f, g, Su, Ta-Chen h, i, j, k, ⁎
Publikováno v:
In Chemosphere September 2024 364
Autor:
Tsutomu Hirano, Toshiyuki Hayashi, Hiroe Sugita, Atsuko Tamasawa, Satoshi Goto, Masako Tomoyasu, Takeshi Yamamoto, Makoto Ohara, Michishige Terasaki, Hideki Kushima, Yasuki Ito, Sho‐ichi Yamagishi, Yusaku Mori
Publikováno v:
Journal of Diabetes Investigation, Vol 14, Iss 12, Pp 1401-1411 (2023)
Abstract Aims/Introduction Small dense low‐density lipoprotein (sdLDL) is a more potent atherogenic lipoprotein than LDL. As sdLDL‐cholesterol (C) levels are determined by triglyceride and LDL‐C levels, pemafibrate and statins can reduce sdLDL
Externí odkaz:
https://doaj.org/article/7b723e31cf984844b51b51d4814f39f0
Autor:
Mahmood, Tahir a, Miles, Joshua R. a, Minnier, Jessica a, d, Tavori, Hagai a, DeBarber, Andrea E. c, Fazio, Sergio a, Shapiro, Michael D. b, ⁎
Publikováno v:
In Journal of Clinical Lipidology January-February 2024 18(1):e50-e58
Publikováno v:
Lipids in Health and Disease, Vol 22, Iss 1, Pp 1-13 (2023)
Abstract Background Small dense low-density lipoprotein cholesterol (sdLDL-C) is the lipoprotein marker among the various lipoproteins that is most strongly related to atherosclerosis. Insulin resistance (IR) can alter lipid metabolism, and sdLDL-C i
Externí odkaz:
https://doaj.org/article/dbaecb2e8a4b424fb634919200a80f90
Autor:
Tsutomu Hirano, Yasuki Ito
Publikováno v:
Journal of Diabetes Investigation, Vol 14, Iss 7, Pp 902-906 (2023)
Abstract The Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) trial failed to show the preventive effects of pemafibrate, a triglyceride (TG)‐lowering drug, on atherosclerotic cardiovascu
Externí odkaz:
https://doaj.org/article/b9ada207d6e34803871a06ebc11f2eec